Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

T-Therapeutics Ltd.

T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge. The company was created to harness the power of T cell biology, evolved over millions of years, to create safe and effective treatments for many cancers and autoimmune diseases. We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs. These TCRs are directed at multiple target classes, many of which have never been worked on before. We are developing a pipeline of first-in-class drugs that will become transformative medicines, reshaping the clinical landscape for patients with cancer or autoimmune diseases. *


Period Start 2022-05-10 established (s-off)
  Predecessor University of Cambridge
Products Industry TCR engineering technology (T-cell receptor engineering technology)
  Industry 2 transgenic mouse
Persons Person Bradley, Allan (Wellcome Trust 200011– Professor Sanger Institute before Howard Hughes Medical Institute)
  Person 2 Seghezzi, Graziano (Sofinnova Partners 200806 Partner)
Region Region Cambridge, Cambridgeshire
  Country United Kingdom (GB)
  Street 3 Riverside, Suite 1
Granta Park
  City CB21 6AD Cambridge, Cambridgeshire
    Address record changed: 2023-11-16
Basic data Employees n. a.
    * Document for »About Section«: T-Therapeutics Ltd.. (11/15/23). "Press Release: T-Therapeutics Raises £48 Million Series A for Development of Next Generation TCR Therapeutics to Transform Cancer Treatment". Cambridge.
Record changed: 2024-01-28


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for T-Therapeutics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x300px

» top